Tags

Type your tag names separated by a space and hit enter

Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjögren's syndrome.
Clin Exp Rheumatol. 2012 Sep-Oct; 30(5):686-92.CE

Abstract

OBJECTIVES

To evaluate how determination of antibodies against the Ro52 antigen influences the classification and clinical characterisation of patients with suspected primary Sjögren's syndrome (SS).

METHODS

The cohort study included 187 patients who fulfilled at least four of the six 1993 SS classification criteria, including positive autoantibodies (antinuclear antibodies [ANA], rheumatoid factor [RF], anti-Ro/SSA and/or anti-La/SS-B antibodies) as mandatory criterium. Anti-Ro/SSA antibodies were tested by qualitative ELISA using a commercial assay. Anti-Ro52 antibodies were detected by a semiquantitative ELISA.

RESULTS

Anti-Ro52 antibodies were found in 70/187 (37%) patients. A significant percentage of patients with anti-Ro/SSA antibodies were negative for anti-Ro52 antibodies (22%), while 13 patients (12%) were negative for anti-Ro/SSA antibodies but positive for anti-Ro52 antibodies, meaning that they fulfilled the 2002 SS criteria while avoiding the need for a salivary biopsy. Higher mean titers of anti-Ro52 antibodies were associated with severe scintigraphic involvement, positive salivary gland biopsy, parotid enlargement, anaemia, leukopenia and RF. A statistical correlation was found between anti-Ro52 titers and age, gammaglobulin levels, RF titers and serum IgA and IgG. Patients with positive anti-Ro/SSA and anti-Ro52 antibodies had a higher frequency of positive salivary gland biopsy, parotid enlargement and positive RF, and higher levels of serum IgG and IgA levels in comparison with patients with positive anti-Ro/SSA but negative anti-Ro52 antibodies.

CONCLUSIONS

Anti-Ro52 antibodies were closely associated with the main clinical, histopathological and immunological features of primary SS. Anti-Ro52 autoantibody testing may help to identify a specific subset of SS patients with more aggressive disease, in whom a closer follow-up and earlier, more robust therapeutic management may be necessary.

Links

Publisher Full Text

Authors+Show Affiliations

Retamozo S
Department Autoimmune Diseases, Hospital Clinic, Barcelona, Spain. soleretamozo@hotmail.com
Akasbi M
No affiliation info available
Brito-Zerón P
No affiliation info available
Bosch X
No affiliation info available
Bove A
No affiliation info available
Perez-de-Lis M
No affiliation info available
Jimenez I
No affiliation info available
Soto-Cardenas MJ
No affiliation info available
Gandia M
No affiliation info available
Diaz-Lagares C
No affiliation info available
Viñas O
No affiliation info available
Siso A
No affiliation info available
Perez-Alvarez R
No affiliation info available
Yague J
No affiliation info available
Ramos-Casals M
No affiliation info available

MeSH

Antibodies, AntinuclearBiomarkersBiopsyChi-Square DistributionEnzyme-Linked Immunosorbent AssayFemaleHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisPredictive Value of TestsPrognosisRheumatoid FactorRibonucleoproteinsSalivary GlandsSjogren's Syndrome

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22704838

Citation

Retamozo, Soledad, et al. "Anti-Ro52 Antibody Testing Influences the Classification and Clinical Characterisation of Primary Sjögren's Syndrome." Clinical and Experimental Rheumatology, vol. 30, no. 5, 2012, pp. 686-92.
Retamozo S, Akasbi M, Brito-Zerón P, et al. Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjögren's syndrome. Clin Exp Rheumatol. 2012;30(5):686-92.
Retamozo, S., Akasbi, M., Brito-Zerón, P., Bosch, X., Bove, A., Perez-de-Lis, M., Jimenez, I., Soto-Cardenas, M. J., Gandia, M., Diaz-Lagares, C., Viñas, O., Siso, A., Perez-Alvarez, R., Yague, J., & Ramos-Casals, M. (2012). Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 30(5), 686-92.
Retamozo S, et al. Anti-Ro52 Antibody Testing Influences the Classification and Clinical Characterisation of Primary Sjögren's Syndrome. Clin Exp Rheumatol. 2012 Sep-Oct;30(5):686-92. PubMed PMID: 22704838.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjögren's syndrome. AU - Retamozo,Soledad, AU - Akasbi,Miriam, AU - Brito-Zerón,Pilar, AU - Bosch,Xavier, AU - Bove,Albert, AU - Perez-de-Lis,Marta, AU - Jimenez,Iratxe, AU - Soto-Cardenas,Maria-Jose, AU - Gandia,Miriam, AU - Diaz-Lagares,Candido, AU - Viñas,Odette, AU - Siso,Antoni, AU - Perez-Alvarez,Roberto, AU - Yague,Jordi, AU - Ramos-Casals,Manuel, Y1 - 2012/10/17/ PY - 2011/08/02/received PY - 2011/12/13/accepted PY - 2012/6/19/entrez PY - 2012/6/19/pubmed PY - 2013/2/8/medline SP - 686 EP - 92 JF - Clinical and experimental rheumatology JO - Clin. Exp. Rheumatol. VL - 30 IS - 5 N2 - OBJECTIVES: To evaluate how determination of antibodies against the Ro52 antigen influences the classification and clinical characterisation of patients with suspected primary Sjögren's syndrome (SS). METHODS: The cohort study included 187 patients who fulfilled at least four of the six 1993 SS classification criteria, including positive autoantibodies (antinuclear antibodies [ANA], rheumatoid factor [RF], anti-Ro/SSA and/or anti-La/SS-B antibodies) as mandatory criterium. Anti-Ro/SSA antibodies were tested by qualitative ELISA using a commercial assay. Anti-Ro52 antibodies were detected by a semiquantitative ELISA. RESULTS: Anti-Ro52 antibodies were found in 70/187 (37%) patients. A significant percentage of patients with anti-Ro/SSA antibodies were negative for anti-Ro52 antibodies (22%), while 13 patients (12%) were negative for anti-Ro/SSA antibodies but positive for anti-Ro52 antibodies, meaning that they fulfilled the 2002 SS criteria while avoiding the need for a salivary biopsy. Higher mean titers of anti-Ro52 antibodies were associated with severe scintigraphic involvement, positive salivary gland biopsy, parotid enlargement, anaemia, leukopenia and RF. A statistical correlation was found between anti-Ro52 titers and age, gammaglobulin levels, RF titers and serum IgA and IgG. Patients with positive anti-Ro/SSA and anti-Ro52 antibodies had a higher frequency of positive salivary gland biopsy, parotid enlargement and positive RF, and higher levels of serum IgG and IgA levels in comparison with patients with positive anti-Ro/SSA but negative anti-Ro52 antibodies. CONCLUSIONS: Anti-Ro52 antibodies were closely associated with the main clinical, histopathological and immunological features of primary SS. Anti-Ro52 autoantibody testing may help to identify a specific subset of SS patients with more aggressive disease, in whom a closer follow-up and earlier, more robust therapeutic management may be necessary. SN - 0392-856X UR - https://www.unboundmedicine.com/medline/citation/22704838/Anti_Ro52_antibody_testing_influences_the_classification_and_clinical_characterisation_of_primary_Sjögren's_syndrome_ L2 - http://www.clinexprheumatol.org/pubmed/find-pii.asp?pii=22704838 DB - PRIME DP - Unbound Medicine ER -